IBT julkaisut 2011
HUOMIO: Tämä luettelo ei ole ehdottoman täydellinen, koska se on koostettu automaattisesti PubMed-tietokannasta. Sama julkaisu voi esiintyä kahteen tai useampaan kertaan, koska aineisto koostetaan tutkimusryhmittäin. Luettelo voi myös sisältää artikkeita, jotka eivät ole IBT:n (aiemmin IMT:n tai Regean) tutkijoiden kirjoittamia johtuen samannimisistä kirjoittajista. |
|
Bioinformatics Mauno Vihinen - Bioinformatics Group |
| Auerbach AD, Burn J, Cassiman JJ, Claustres M, Cotton RG, Cutting G, den Dunnen JT, El-Ruby M, Vargas AF, Greenblatt MS, Macrae F, Matsubara Y, Rimoin DL, Vihinen M, Van Broeckhoven C Mutation (variation) databases and registries: a rationale for coordination of efforts. Nat Rev Genet 2011 ;12(12)881; discussion 881 PMID |
| Dalgleish R, Oetting WS, Auerbach AD, Beckmann JS, Cambon-Thomsen A, Devereau A, Greenblatt MS, Patrinos GP, Taylor GR, Vihinen M, Brookes AJ Clarity and claims in variation/mutation databasing. Nat Biotechnol 2011 ;29(9)790-2; author reply 792-4 PMID |
| Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H, Tammela TL, Wahlfors T, Schleutker J NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene. BMC Cancer 2011 ;11327 PMID |
| Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011 ;6(3)e17979 PMID |
| Thusberg J, Olatubosun A, Vihinen M Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 2011 ;32(4)358-68 PMID |
| Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011 ;13(1)R20 PMID |
| Laurila K, Vihinen M PROlocalizer: integrated web service for protein subcellular localization prediction. Amino Acids 2011 ;40(3)975-80 PMID |
|
Biotechnology Vesa Hytönen - Protein Dynamics Markku Kulomaa - Molecular Biotechnology |
| Linko V, Leppiniemi J, Shen B, Niskanen E, Hytönen VP, Toppari JJ Growth of immobilized DNA by polymerase: bridging nanoelectrodes with individual dsDNA molecules. Nanoscale 2011 ;3(9)3788-92 PMID |
| Heikkinen JJ, Kivimäki L, Määttä JA, Mäkelä I, Hakalahti L, Takkinen K, Kulomaa MS, Hytönen VP, Hormi OE Versatile bio-ink for covalent immobilization of chimeric avidin on sol-gel substrates. Colloids Surf B Biointerfaces 2011 ;87(2)409-14 PMID |
| Bootorabi F, Jänis J, Hytönen VP, Valjakka J, Kuuslahti M, Vullo D, Niemelä O, Supuran CT, Parkkila S Acetaldehyde-derived modifications on cytosolic human carbonic anhydrases. J Enzyme Inhib Med Chem 2011 ;26(6)862-70 PMID |
| Riihimäki TA, Hiltunen S, Rangl M, Nordlund HR, Määttä JA, Ebner A, Hinterdorfer P, Kulomaa MS, Takkinen K, Hytönen VP Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein. BMC Biotechnol 2011 ;1164 PMID |
| Riihimäki TA, Kukkurainen S, Varjonen S, Hörhä J, Nyholm TK, Kulomaa MS, Hytönen VP Construction of chimeric dual-chain avidin by tandem fusion of the related avidins. PLoS One 2011 ;6(5)e20535 PMID |
| Linko V, Leppiniemi J, Paasonen ST, Hytönen VP, Toppari JJ Defined-size DNA triple crossover construct for molecular electronics: modification, positioning and conductance properties. Nanotechnology 2011 ;22(27)275610 PMID |
| Heikkinen JJ, Riihimäki TA, Määttä JA, Suomela SE, Kantomaa J, Kulomaa MS, Hytönen VP, Hormi OE Covalent biofunctionalization of cellulose acetate with thermostable chimeric avidin. ACS Appl Mater Interfaces 2011 ;3(7)2240-5 PMID |
| Leppiniemi J, Määttä JA, Hammaren H, Soikkeli M, Laitaoja M, Jänis J, Kulomaa MS, Hytönen VP Bifunctional avidin with covalently modifiable ligand binding site. PLoS One 2011 ;6(1)e16576 PMID |
| Nurminen K, Blazevic V, Huhti L, Räsänen S, Koho T, Hytönen VP, Vesikari T Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011 ;83(3)525-31 PMID |
| Määttä JA, Eisenberg-Domovich Y, Nordlund HR, Hayouka R, Kulomaa MS, Livnah O, Hytönen VP Chimeric avidin shows stability against harsh chemical conditions--biochemical analysis and 3D structure. Biotechnol Bioeng 2011 ;108(3)481-90 PMID |
| Heikkinen JJ, Kivimäki L, Määttä JA, Mäkelä I, Hakalahti L, Takkinen K, Kulomaa MS, Hytönen VP, Hormi OE Versatile bio-ink for covalent immobilization of chimeric avidin on sol-gel substrates. Colloids Surf B Biointerfaces 2011 ;87(2)409-14 PMID |
| Riihimäki TA, Hiltunen S, Rangl M, Nordlund HR, Määttä JA, Ebner A, Hinterdorfer P, Kulomaa MS, Takkinen K, Hytönen VP Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein. BMC Biotechnol 2011 ;1164 PMID |
| Riihimäki TA, Kukkurainen S, Varjonen S, Hörhä J, Nyholm TK, Kulomaa MS, Hytönen VP Construction of chimeric dual-chain avidin by tandem fusion of the related avidins. PLoS One 2011 ;6(5)e20535 PMID |
| Heikkinen JJ, Riihimäki TA, Määttä JA, Suomela SE, Kantomaa J, Kulomaa MS, Hytönen VP, Hormi OE Covalent biofunctionalization of cellulose acetate with thermostable chimeric avidin. ACS Appl Mater Interfaces 2011 ;3(7)2240-5 PMID |
| Leppiniemi J, Määttä JA, Hammaren H, Soikkeli M, Laitaoja M, Jänis J, Kulomaa MS, Hytönen VP Bifunctional avidin with covalently modifiable ligand binding site. PLoS One 2011 ;6(1)e16576 PMID |
| Määttä JA, Eisenberg-Domovich Y, Nordlund HR, Hayouka R, Kulomaa MS, Livnah O, Hytönen VP Chimeric avidin shows stability against harsh chemical conditions--biochemical analysis and 3D structure. Biotechnol Bioeng 2011 ;108(3)481-90 PMID |
|
Cancer Groups Jorma Isola - Cancer Biology Anne Kallioniemi - Cancer Genomics Tapio Visakorpi - Molecular Biology of Prostate Cancer Hans Lilja - Prostate Cancer Biomarkers |
| Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res 2011 ;13(6)R134 PMID |
| Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins. PLoS One 2011 ;6(11)e27152 PMID |
| Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T Overall and worst gleason scores are equally good predictors of prostate cancer progression. BMC Urol 2011 ;1121 PMID |
| Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011 ;12(12)1134-42 PMID |
| Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 2011 ;13(5)R87 PMID |
| Tothova V, Isola J, Parkkila S, Kopacek J, Pastorek J, Pastorekova S, Gibadulinova A Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein. J Cell Biochem 2011 ;112(11)3373-84 PMID |
| Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer. BJU Int 2011 ;108(9)1430-8 PMID |
| Barok M, Tanner M, Köninki K, Isola J Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011 ;13(2)R46 PMID |
| Tolonen TT, Kujala PM, Laurila M, Tirkkonen M, Ilvesaro J, Tuominen VJ, Tammela TL, Isola J Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. Hum Pathol 2011 ;42(11)1635-42 PMID |
| Barok M, Tanner M, Köninki K, Isola J Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011 ;306(2)171-9 PMID |
| Junttila TT, Tanner M, Isola J [Targeted cytotoxic drugs emerging for cancer therapy]. Duodecim 2011 ;127(4)343-9 PMID |
| Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 2011 ;113 PMID |
| Lassus H, Staff S, Leminen A, Isola J, Butzow R Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol 2011 ;120(1)11-7 PMID |
| Rodriguez-Martinez A, Alarmo EL, Saarinen L, Ketolainen J, Nousiainen K, Hautaniemi S, Kallioniemi A Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. BMC Med Genomics 2011 ;480 PMID |
| Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins. PLoS One 2011 ;6(11)e27152 PMID |
| Virtanen S, Alarmo EL, Sandström S, Ampuja M, Kallioniemi A Bone morphogenetic protein -4 and -5 in pancreatic cancer--novel bidirectional players. Exp Cell Res 2011 ;317(15)2136-46 PMID |
| Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 2011 ;20(16)3278-88 PMID |
| Kuuselo R, Savinainen K, Sandström S, Autio R, Kallioniemi A MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. Int J Cancer 2011 ;129(11)2553-65 PMID |
| Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. PLoS One 2011 ;6(10)e26595 PMID |
| Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T Overall and worst gleason scores are equally good predictors of prostate cancer progression. BMC Urol 2011 ;1121 PMID |
| Furusato B, van Leenders GJ, Trapman J, Kimura T, Egawa S, Takahashi H, Furusato M, Visakorpi T, Hano H Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int 2011 ;61(7)409-14 PMID |
| Renkonen R, Björkroth J, Helve O, Louhimo J, Rautava P, Remes A, Seppälä T, Turunen JP, Virjo I, Visakorpi T, Heikinheimo M [Are there enough medical scientists in Finland?]. Duodecim 2011 ;127(10)1003-9 PMID |
| Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer. BJU Int 2011 ;108(9)1430-8 PMID |
| Boormans JL, Porkka K, Visakorpi T, Trapman J Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer. Eur Urol 2011 ;60(1)183-4 PMID |
| Porkka KP, Ogg EL, Saramäki OR, Vessella RL, Pukkila H, Lähdesmäki H, van Weerden WM, Wolf M, Kallioniemi OP, Jenster G, Visakorpi T The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer 2011 ;50(7)499-509 PMID |
| Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011 ;6(3)e17979 PMID |
| Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011 ;59(5)671-81 PMID |
| Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011 ;71(6)604-14 PMID |
| Clauss A, Persson M, Lilja H, Lundwall Å Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products. BMC Biochem 2011 ;1255 PMID |
| Vickers A, Lilja H Editorial comment. Urology 2011 ;78(3)606; author reply 606 PMID |
| Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011 ;60(5)897-904 PMID |
| Végvári A, Rezeli M, Häkkinen J, Sihlbom C, Carlsohn E, Malm J, Lilja H, Laurell T, Marko-Varga G Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples. J Proteomics 2011 ;75(1)202-10 PMID |
| Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011 ;50 Suppl 161-75 PMID |
| Peltola MT, Niemelä P, Alanen K, Nurmi M, Lilja H, Pettersson K Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆). J Immunol Methods 2011 ;369(1-2)74-80 PMID |
| Gupta A, Lilja H Editorial comment. Urology 2011 ;77(4)903-4; author reply 904 PMID |
| Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011 ;103(6)462-9 PMID |
| Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Lilja H A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011 ;20(2)255-61 PMID |
| Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011 ;117(6)1210-9 PMID |
| Christensson A, Bruun L, Björk T, Cronin AM, Vickers AJ, Savage CJ, Lilja H Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. BJU Int 2011 ;107(11)1769-74 PMID |
| O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Møller H, Oliver RT, Berney DM, Foster CS, Eastham JA, Vickers AJ, Lilja H, Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2011 ;128(10)2373-81 PMID |
|
Cellular Biology Ari-Pekka Huovila - Cell Interactions Herma Renkema - Biochemistry of Cell Signaling |
| Raitoharju E, Seppälä I, Levula M, Kuukasjärvi P, Laurikka J, Nikus K, Huovila AP, Oksala N, Klopp N, Illig T, Laaksonen R, Karhunen PJ, Viik J, Lehtinen R, Pelto-Huikko M, Tarkka M, Kähönen M, Lehtimäki T Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts. Atherosclerosis 2011 ;218(1)127-33 PMID |
|
Mitochondrial Genetics Howy Jacobs - Mitochondrial Gene Expression and Disease Group Laurie Kaguni - Mitochondrial Biogenesis in Health and Disease Alberto Sanz - Mitochondrial Gerontology and Age-related Diseases Hans Spelbrink - Molecular Biology-Mitochondrial DNA maintenance |
| Rubio-Cosials A, Sidow JF, Jiménez-Menéndez N, Fernández-Millán P, Montoya J, Jacobs HT, Coll M, Bernadó P, Solà M Human mitochondrial transcription factor A induces a U-turn structure in the light strand promoter. Nat Struct Mol Biol 2011 ;18(11)1281-9 PMID |
| Häkkinen A, Healy S, Jacobs HT, Ribeiro AS Genome wide study of NF-Y type CCAAT boxes in unidirectional and bidirectional promoters in human and mouse. J Theor Biol 2011 ;281(1)74-83 PMID |
| Hyvärinen AK, Pohjoismäki JL, Holt IJ, Jacobs HT Overexpression of MTERFD1 or MTERFD3 impairs the completion of mitochondrial DNA replication. Mol Biol Rep 2011 ;38(2)1321-8 PMID |
| Oliveira MT, Kaguni LS Reduced stimulation of recombinant DNA polymerase γ and mitochondrial DNA (mtDNA) helicase by variants of mitochondrial single-stranded DNA-binding protein (mtSSB) correlates with defects in mtDNA replication in animal cells. J Biol Chem 2011 ;286(47)40649-58 PMID |
| Euro L, Farnum GA, Palin E, Suomalainen A, Kaguni LS Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol γ. Nucleic Acids Res 2011 ;39(21)9072-84 PMID |
| Leeuwenburgh C, Pamplona R, Sanz A Mitochondria and aging. J Aging Res 2011 ;2011782946 PMID |
| Stefanatos R, Sanz A Mitochondrial complex I: a central regulator of the aging process. Cell Cycle 2011 ;10(10)1528-32 PMID |
| Pohjoismäki JL, Goffart S, Spelbrink JN Replication stalling by catalytically impaired Twinkle induces mitochondrial DNA rearrangements in cultured cells. Mitochondrion 2011 ;11(4)630-4 PMID |
| Atanassova N, Fusté JM, Wanrooij S, Macao B, Goffart S, Bäckström S, Farge G, Khvorostov I, Larsson NG, Spelbrink JN, Falkenberg M Sequence-specific stalling of DNA polymerase γ and the effects of mutations causing progressive ophthalmoplegia. Hum Mol Genet 2011 ;20(6)1212-23 PMID |
|
Molecular Immunology Dan Hultmark - Genetic Immunology Marko Pesu - Immunoregulation Mika Rämet - Experimental Immunology Olli Silvennoinen - Molecular Immunology |
| Ekström JO, Habayeb MS, Srivastava V, Kieselbach T, Wingsle G, Hultmark D Drosophila Nora virus capsid proteins differ from those of other picorna-like viruses. Virus Res 2011 ;160(1-2)51-8 PMID |
| Ulvila J, Vanha-aho LM, Kleino A, Vähä-Mäkilä M, Vuoksio M, Eskelinen S, Hultmark D, Kocks C, Hallman M, Parikka M, Rämet M Cofilin regulator 14-3-3zeta is an evolutionarily conserved protein required for phagocytosis and microbial resistance. J Leukoc Biol 2011 ;89(5)649-59 PMID |
| Pesu M Mutant JAK3 FERMents ATLL. Blood 2011 ;118(14)3759-60 PMID |
| Marttila S, Jylhävä J, Pesu M, Hämäläinen S, Jylhä M, Hervonen A, Hurme M IL-7 concentration is increased in nonagenarians but is not associated with markers of T cell immunosenescence. Exp Gerontol 2011 ;46(12)1000-2 PMID |
| Turpeinen H, Raitoharju E, Oksanen A, Oksala N, Levula M, Lyytikäinen LP, Järvinen O, Creemers JW, Kähönen M, Laaksonen R, Pelto-Huikko M, Lehtimäki T, Pesu M Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL. Atherosclerosis 2011 ;219(2)799-806 PMID |
| Valanne S, Rämet M [Fruit fly--genetically excellent model animal for research]. Duodecim 2011 ;127(19)2063-71 PMID |
| Ulvila J, Vanha-Aho LM, Rämet M Drosophila phagocytosis - still many unknowns under the surface. APMIS 2011 ;119(10)651-62 PMID |
| Valanne S, Wang JH, Rämet M The Drosophila Toll signaling pathway. J Immunol 2011 ;186(2)649-56 PMID |
| Ulvila J, Vanha-aho LM, Kleino A, Vähä-Mäkilä M, Vuoksio M, Eskelinen S, Hultmark D, Kocks C, Hallman M, Parikka M, Rämet M Cofilin regulator 14-3-3zeta is an evolutionarily conserved protein required for phagocytosis and microbial resistance. J Leukoc Biol 2011 ;89(5)649-59 PMID |
| Rämet M, Korppi M, Hallman M Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making? Pediatr Pulmonol 2011 ;46(2)101-10 PMID |
| Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert TA, Skoda RC, Hubbard SR, Silvennoinen O The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011 ;18(9)971-6 PMID |
| Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS One 2011 ;6(4)e18522 PMID |
| Dong L, Zhang X, Fu X, Zhang X, Gao X, Zhu M, Wang X, Yang Z, Jensen ON, Saarikettu J, Yao Z, Silvennoinen O, Yang J PTB-associated splicing factor (PSF) functions as a repressor of STAT6-mediated Ig epsilon gene transcription by recruitment of HDAC1. J Biol Chem 2011 ;286(5)3451-9 PMID |
|
Regenerative Medicine Katriina Aalto-Setälä - Cardiology Group Susanna Miettinen - Adult Stem Cell Group Susanna Narkilahti - Neuro Group Heli Skottman - Ophthalmology Group |
| Kujala VJ, Jimenez ZC, Väisänen J, Tanskanen JM, Kerkelä E, Hyttinen J, Aalto-Setälä K Averaging in vitro cardiac field potential recordings obtained with microelectrode arrays. Comput Methods Programs Biomed 2011 ;104(2)199-205 PMID |
| Rajala K, Pekkanen-Mattila M, Aalto-Setälä K Cardiac differentiation of pluripotent stem cells. Stem Cells Int 2011 ;2011383709 PMID |
| Frantzén J, Pälli A, Kotilainen E, Heino H, Mannerström B, Huhtala H, Kuokkanen H, Sándor GK, Leino K, Röyttä M, Parkkola R, Suuronen R, Miettinen S, Aro HT, Haimi S In Vivo and In Vitro Study of a Polylactide-Fiber-Reinforced β-Tricalcium Phosphate Composite Cage in an Ovine Anterior Cervical Intercorporal Fusion Model. Int J Biomater 2011 ;2011109638 PMID |
| Tirkkonen L, Halonen H, Hyttinen J, Kuokkanen H, Sievänen H, Koivisto AM, Mannerström B, Sándor GK, Suuronen R, Miettinen S, Haimi S The effects of vibration loading on adipose stem cell number, viability and differentiation towards bone-forming cells. J R Soc Interface 2011 ;8(65)1736-47 PMID |
| Thesleff T, Lehtimäki K, Niskakangas T, Mannerström B, Miettinen S, Suuronen R, Öhman J Cranioplasty with adipose-derived stem cells and biomaterial: a novel method for cranial reconstruction. Neurosurgery 2011 ;68(6)1535-40 PMID |
| Sartoneva R, Haimi S, Miettinen S, Mannerström B, Haaparanta AM, Sándor GK, Kellomäki M, Suuronen R, Lahdes-Vasama T Comparison of a poly-L-lactide-co-ε-caprolactone and human amniotic membrane for urothelium tissue engineering applications. J R Soc Interface 2011 ;8(58)671-7 PMID |
| Lindroos B, Suuronen R, Miettinen S The potential of adipose stem cells in regenerative medicine. Stem Cell Rev 2011 ;7(2)269-91 PMID |
| Sundberg M, Hyysalo A, Skottman H, Shin S, Vemuri M, Suuronen R, Narkilahti S A xeno-free culturing protocol for pluripotent stem cell-derived oligodendrocyte precursor cell production. Regen Med 2011 ;6(4)449-60 PMID |
| Shalaby A, Mennander A, Rinne T, Oksala N, Aanismaa R, Narkilahti S, Paavonen T, Laurikka J, Tarkka M Aquaporin-7 expression during coronary artery bypass grafting with diazoxide. Scand Cardiovasc J 2011 ;45(6)354-9 PMID |
| Vaajasaari H, Ilmarinen T, Juuti-Uusitalo K, Rajala K, Onnela N, Narkilahti S, Suuronen R, Hyttinen J, Uusitalo H, Skottman H Toward the defined and xeno-free differentiation of functional human pluripotent stem cell-derived retinal pigment epithelial cells. Mol Vis 2011 ;17558-75 PMID |
| , Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC, Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E, Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De Sousa PA, Denning C, Downie J, Dvorak P, Montgomery KD, Feki A, Ford A, Fox V, Fraga AM, Frumkin T, Ge L, Gokhale PJ, Golan-Lev T, Gourabi H, Gropp M, Lu G, Hampl A, Harron K, Healy L, Herath W, Holm F, Hovatta O, Hyllner J, Inamdar MS, Irwanto AK, Ishii T, Jaconi M, Jin Y, Kimber S, Kiselev S, Knowles BB, Kopper O, Kukharenko V, Kuliev A, Lagarkova MA, Laird PW, Lako M, Laslett AL, Lavon N, Lee DR, Lee JE, Li C, Lim LS, Ludwig TE, Ma Y, Maltby E, Mateizel I, Mayshar Y, Mileikovsky M, Minger SL, Miyazaki T, Moon SY, Moore H, Mummery C, Nagy A, Nakatsuji N, Narwani K, Oh SK, Oh SK, Olson C, Otonkoski T, Pan F, Park IH, Pells S, Pera MF, Pereira LV, Qi O, Raj GS, Reubinoff B, Robins A, Robson P, Rossant J, Salekdeh GH, Schulz TC, Sermon K, Sheik Mohamed J, Shen H, Sherrer E, Sidhu K, Sivarajah S, Skottman H, Spits C, Stacey GN, Strehl R, Strelchenko N, Suemori H, Sun B, Suuronen R, Takahashi K, Tuuri T, Venu P, Verlinsky Y, Ward-van Oostwaard D, Weisenberger DJ, Wu Y, Yamanaka S, Young L, Zhou Q Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 2011 ;29(12)1132-44 PMID |
| Sundberg M, Hyysalo A, Skottman H, Shin S, Vemuri M, Suuronen R, Narkilahti S A xeno-free culturing protocol for pluripotent stem cell-derived oligodendrocyte precursor cell production. Regen Med 2011 ;6(4)449-60 PMID |
| Vaajasaari H, Ilmarinen T, Juuti-Uusitalo K, Rajala K, Onnela N, Narkilahti S, Suuronen R, Hyttinen J, Uusitalo H, Skottman H Toward the defined and xeno-free differentiation of functional human pluripotent stem cell-derived retinal pigment epithelial cells. Mol Vis 2011 ;17558-75 PMID |
Biolääketieteellisen teknologian yksikkö
Biokatu 8
33520 Tampere, Finland
Biokatu 8
33520 Tampere, Finland
